MT. OLIVE, N.J., May 9 /PRNewswire/ -- InSet Technologies, an emerging leader in the development of implantable drug infusion pumps for targeted delivery of medications, announced today the addition of Jon Tremmel to its Board of Directors.
Before retiring from Medtronic Inc. after nearly 30 years of service, Jon held a number of senior leadership positions including President of the Neurological Division, President of the Physio-Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division.
"InSet Technologies has a very innovative product in clinical trials right now, and I look forward to being part of this growing company," said Jon Tremmel. "I have spent most of my career seeking technological solutions to help patients manage chronic conditions. None is more important to me than finding more effective methods to manage the debilitating conditions of chronic pain."
Mr. Tremmel also has served as a key member of the Medtronic Senior Management Operating Committee. He achieved a Masters Degree in Engineering from Boston University and a MBA from the University of Minnesota. Jon presently resides in Minneapolis, Minnesota, with his family and is an active member of the Minnesota Zoo Board, in addition to various Board positions for other companies.
"InSet has made substantial progress in the development of a new generation of implantable drug infusion pump technologies. Jon brings a wealth of business expertise that will contribute to our growth and enhance value to our shareholders," said Steve Adler, President and CEO of Inset Technologies. "We look forward to his contribution to our company at this important time in our history."
InSet Technologies Incorporated (http://www.insetinc.com) headquartered in Mt. Olive, NJ is a development-stage medical device company. Its first product, the Prometra(R) programmable, implantable drug infusion pump is undergoing clinical trials for the treatment of chronic pain. About 70 million people in the United States live with chronic pain. Chronic pain costs the U.S. more in lost productivity and treatment than heart disease and cancer combined.
CAUTION: Prometra(R) pumps are Investigational Devices, which have not yet been approved by the FDA.
|SOURCE InSet Technologies|
Copyright©2008 PR Newswire.
All rights reserved